儿童急诊科就诊的COVID-19疾病:8886例多中心研究
这项多中心回顾性观察性队列研究纳入19家三级医院儿童急诊科2020年3月11日至2021年5月31日期间8886例SARS-CoV-2 PCR阳性或血清特异性抗体阳性的儿童。99.0%为PCR阳性,1.0%诊断为MIS-C。PCR阳性患者中15.5%无症状,最常见症状为发热(48.5%)和咳嗽(30.7%);0.9%为重型-危重型,14.4%住院,1.2%入住PICU。MIS-C患者中60.9%为男性,中位年龄6.4岁,13.7%出现休克,89.7%住院,29.9%入住PICU。多数PCR阳性儿童临床过程轻微,但MIS-C是严重后果。
要点
- 8886例中99.0%(8799例)为SARS-CoV-2 PCR阳性,1.0%(87例)诊断为MIS-C。
- PCR阳性患者中15.5%无症状,最常见症状为发热48.5%和咳嗽30.7%;<1岁组发热率最高达69.6%,发热率随年龄增长而下降(p < 0.001)。
- PCR阳性患者中重型-危重型仅0.9%(83例),住院14.4%(1269例),PICU入住1.2%(106例)。
- MIS-C患者中60.9%为男性,中位年龄6.4岁(IQR 3.9-10.4),13.7%(12例)出现休克,住院89.7%,PICU入住29.9%。
- 67.3%的病例有已知SARS-CoV-2 PCR阳性接触史,其中71.3%为家庭接触。
适用人群与场景
- 2020年3月11日至2021年5月31日期间就诊于19家三级医院儿童急诊科、鼻咽/气管标本SARS-CoV-2 PCR阳性或血清特异性抗体阳性的儿童。
诊断标准与关键阈值
- SARS-CoV-2确诊:鼻咽/气管标本PCR阳性或血清特异性抗体阳性。
红旗征与不能漏的情况
- MIS-C患者中13.7%(12例)出现休克,需警惕。
- MIS-C患者PICU入住率达29.9%,病情严重。
研究设计与关键结果
- 多中心回顾性观察性队列研究,19家三级医院儿童急诊科,纳入8886例。
- 99.0%(8799例)为SARS-CoV-2 PCR阳性,1.0%(87例)诊断为MIS-C。
- PCR阳性患者中51.0%为男性,8.5%有慢性病,中位年龄11.6岁(IQR 5.0-15.4),8.4%(737例)年龄<1岁。
- PCR阳性患者中15.5%无症状,最常见症状为发热48.5%和咳嗽30.7%;发热率随年龄增长而下降(p < 0.001),<1岁组发热率最高为69.6%。
- 67.3%的病例有已知SARS-CoV-2 PCR阳性接触史,其中71.3%为家庭接触。
- PCR阳性患者中重型-危重型0.9%(83例),住院14.4%(1269例),PICU入住1.2%(106例)。
- MIS-C患者中60.9%为男性,中位年龄6.4岁(IQR 3.9-10.4),13.7%(12例)出现休克,住院89.7%,PICU入住29.9%。
证据类型、等级与局限
- 证据类型:多中心回顾性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 多数SARS-CoV-2 PCR阳性儿童临床过程轻微,但MIS-C虽罕见却可导致频繁PICU入住,作者认为进一步理解COVID-19疾病特征可为靶向人群治疗策略的开发提供见解和指导。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The aim was to evaluate the epidemiological, clinical, laboratory, and radiologic data of children with SARS-CoV-2 positivity by polymerase chain reaction (PCR) together with treatment strategies and clinical outcomes and to evaluate cases of multisystem inflammatory syndrome in children (MIS-C) in this population.
METHODS: This was a multicenter retrospective observational cohort study performed in the pediatric emergency departments of 19 tertiary hospitals. From March 11, 2020, to May 31, 2021, children who were diagnosed with confirmed nasopharyngeal/tracheal specimen SARS-CoV-2 PCR positivity or positivity for serum-specific antibodies against SARS-CoV-2 were included. Demographics, presence of chronic illness, symptoms, history of contact with SARS-CoV-2 PCR-positive individuals, laboratory and radiologic investigations, clinical severity, hospital admissions, and prognosis were recorded.
RESULTS: A total of 8886 cases were included. While 8799 (99.0%) cases resulted in a diagnosis of SARS-CoV-2 with PCR positivity, 87 (1.0%) patients were diagnosed with MIS-C. Among SARS-CoV-2 PCR-positive patients, 51.0% were male and 8.5% had chronic illnesses. The median age was 11.6 years (IQR: 5.0-15.4) and 737 (8.4%) patients were aged <1 year. Of the patients, 15.5% were asymptomatic. The most common symptoms were fever (48.5%) and cough (30.7%) for all age groups. There was a decrease in the rate of fever as age increased (p < 0.001); the most common age group for this symptom was <1 year with the rate of 69.6%. There was known contact with a SARS-CoV-2 PCR-positive individual in 67.3% of the cases, with household contacts in 71.3% of those cases. In terms of clinical severity, 83 (0.9%) patients were in the severe-critical group. There was hospital admission in 1269 (14.4%) cases, with 106 (1.2%) of those patients being admitted to the pediatric intensive care unit (PICU). Among patients with MIS-C, 60.9% were male and the median age was 6.4 years (IQR: 3.9-10.4). Twelve (13.7%) patients presented with shock. There was hospital admission in 89.7% of these cases, with 29.9% of the patients with MIS-C being admitted to the PICU.
CONCLUSION: Most SARS-CoV-2 PCR-positive patients presented with a mild clinical course. Although rare, MIS-C emerges as a serious consequence with frequent PICU admission. Further understanding of the characteristics of COVID-19 disease could provide insights and guide the development of therapeutic strategies for target groups.
参考来源
- Duman M, Şık N, Tekşam Ö, et al. COVID-19 Disease in Presenting to the Pediatric Emergency Department: A Multicenter Study of 8886 Cases. Am J Emerg Med. 2022. PMID: 35849960. doi:10.1016/j.ajem.2022.06.015
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。